secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001367644-24-000058
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings
--------------------------------------------------------------------------------

- Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.
- Closes Baltimore-Bayview Drug Substance and Rockville Drug Product manufacturing facilities.
- Estimated charges of $18-21M primarily in H2 2024; expects annualized savings of ~$80M.
- Operations concentrated at Winnipeg and Lansing; new Chief Science Officer role created.
- Q1 2024 earnings to be reported May 1; also filed amendment to credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/0001367644-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/ebs-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer